Brean Capital reiterated its Sell rating on Rockwell Medical Inc (NASDAQ: RMTI) on Monday following the FDA approval of its Triferic iron replacement product.
The firm maintained a $4 price target.
Analysts Jonathan Aschoff and Yi Cheng...
Oops! Unable to complete your request. Please refresh your browser.
Companies in this industry provide dialysis services to patients with diabetes. These companies make a substantial portion of their revenue from prescribing diabetes drugs. They also heavily dependent on Medicare and Medicaid.